LBRX

Healthcare Biotechnology

LB Pharmaceuticals Inc

$36.99

-0.29 -0.78% today

Price History

Not enough data

Key Stats

Market Cap

1.19B

Avg Volume

335,520

EPS

-$5.10

52W High

$50.16

52W Low

$14.32

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-7.35

P/B Ratio

3.19

EV/EBITDA

-9.56

Margins

Gross Margin 0.0%

Operating Margin 0.0%

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(50.0%)

Return on Assets

(30.0%)

Liquidity & Leverage

Current Ratio

15.08

Quick Ratio

13.91

Debt / Equity

0.02

Total Cash

327.79M

Total Debt

5.22M

About

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

lbpharma.us